

Anti-CCN2 / CTGF Reference Antibody (pamrevlumab)

Recombinant Antibody Catalog # APR10017

Product Information

Application FC, Kinetics, Animal Model

Primary Accession P29279

Reactivity Human, Mouse, Rat, Rabbit

Clonality Monoclonal

Isotype IgG1 Calculated MW 38091

Additional Information

Target/Specificity CCN2 / CTGF

Endotoxin

Conjugation Unconjugated

Expression system CHO Cell

Format Purified monoclonal antibody supplied in PBS, pH6.0, without

preservative. This antibody is purified through a protein A column.

Protein Information

Name CCN2 (HGNC:2500)

Function Major connective tissue mitoattractant secreted by vascular endothelial

cells. Promotes proliferation and differentiation of chondrocytes. Is involved in the stimulation of osteoblast differentiation and has a critical role in osteogenesis (PubMed:39414788). Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth

factor- induced DNA synthesis.


Cellular Location Secreted, extracellular space, extracellular matrix

{ECO:0000250 | UniProtKB:P29268}. Secreted


Tissue Location Expressed in bone marrow and thymic cells. Also expressed one of two Wilms

tumors tested.


Images




Anti-CCN2 / CTGF Reference Antibody (pamrevlumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CCN2 / CTGF Reference Antibody (pamrevlumab)is more than 100% ,determined by SEC-HPLC.



Immobilized human CTGF His at 2 µg/mL can bind Anti-CCN2 / CTGF Reference Antibody (pamrevlumab),EC50=0.006105 µg/mL.



Pamrevlumab inhibited the tumor growth of COLO205 on Balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 39% at 40 mpk at D31.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.